by James on 5 September 2011
Telcagepant was a promising drug for migraine patients, with possibilities as both an abortive and a preventative. But in July, drug company Merck finally ended the clinical trials with no plans to recontinue them. Merck announced: Merck is discontinuing the clinical development program for telcagepant, the company’s investigational calcitonin gene-related peptide receptor antagonist for the [...]
by James on 22 September 2010
On Monday the announcement came from Global Health Ventures, Inc., that they would be developing a sublingual version of migraine drug telcagepant. Telcagepant, a calcitonin gene-related peptide receptor antagonist, has had a rocky beginning. Hailed in 2008 as the beginning of a new era in migraine treatment, the trials faltered over concerns about preventative use. [...]
by James on 30 April 2010
Drug company Merck is planning to start a new trial for the drug Telcagepant this year, a spokeswoman for the company says. We last talked about this up-and-coming migraine drug back in October (see New Migraine Drug Telcagepant – Not Dead Yet. It shows promise, but Merck stopped trials of Telcagepant as a preventative when [...]
by James on 13 October 2009
The pharmaceutical company Merck & Co., Inc was at the 14th International Headache Congress in September, talking again about the migraine drug Telcagepant. And hopes that Telcagepant will see the light of day aren’t dead yet. After concerns about using Telcagepant as a migraine preventative, Merck has moved ahead with trials using the new drug [...]
The developers of one of the up-and-coming migraine drugs, Telcagepant, announced late last month that it was going to delay taking the drug to the FDA. It looks like the drug could be shelved – but will it be? Financially, telcagepant was to be one of Merck’s new key drugs. But we’re talking about big [...]